4.8 Article

A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Gastroenterology & Hepatology

TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis

Xiaobo Wang et al.

Summary: This study demonstrates that TAZ protein in pre-tumor NASH-hepatocytes promotes damage to the DNA of hepatocytes, contributing to eventual HCC. Targeting TAZ in NASH therapies may prevent NASH-HCC.

JOURNAL OF HEPATOLOGY (2022)

Article Oncology

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Thomas Yau et al.

Summary: First-line nivolumab treatment did not significantly improve overall survival compared with sorafenib in patients with advanced hepatocellular carcinoma, but clinical activity and a favorable safety profile were observed in some patients.

LANCET ONCOLOGY (2022)

Article Gastroenterology & Hepatology

TAZ is indispensable for c-MYC-induced hepatocarcinogenesis

Haichuan Wang et al.

Summary: TAZ is identified as a pivotal player at the crossroad between the c-MYC and Hippo pathways in HCC, playing a critical role in c-MYC-dependent hepatocarcinogenesis and potentially being targeted for the treatment of c-MYC-driven hepatocellular carcinoma patients.

JOURNAL OF HEPATOLOGY (2022)

Article Multidisciplinary Sciences

Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis

Aveline Filliol et al.

Summary: The shift in HSC subpopulations during chronic liver disease is associated with a switch from HCC protection to promotion. Quiescent and cytokine-producing HSCs prevent hepatocyte death and HCC development, while activated myofibroblastic HSCs promote proliferation and tumor development through increased stiffness and TAZ and discoidin domain receptor 1 activation.

NATURE (2022)

Article Medicine, Research & Experimental

Inhibiting SCAP/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis

Satoshi Kawamura et al.

Summary: Inhibition of sterol regulatory element-binding proteins (SREBPs) is not an effective approach for treating nonalcoholic steatohepatitis (NASH), as it exacerbates liver injury and liver cancer development despite reducing hepatic steatosis. Additionally, SREBP inhibition alters lipid composition, causes endoplasmic reticulum stress and hepatocyte injury, but these effects can be mitigated by supplementation with phosphatidylcholines.

JOURNAL OF CLINICAL INVESTIGATION (2022)

Article Medicine, General & Internal

Hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Liver cancer, particularly hepatocellular carcinoma (HCC), poses a significant global health challenge with rising incidence projected to exceed 1 million cases by 2025. Infection by hepatitis B and C viruses remains a major risk factor for HCC, while non-alcoholic steatohepatitis is emerging as a more common risk factor in Western countries. Advances in systemic therapies for HCC, including immunotherapies and targeted therapies, are expected to revolutionize the management of this disease.

NATURE REVIEWS DISEASE PRIMERS (2021)

Article Oncology

Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma

Tracy T. Tang et al.

Summary: Mutations in the NF2 gene leading to dysfunctional Merlin are common in malignant mesothelioma. Compounds selectively inhibiting YAP/TAZ-TEAD gene transcription have been discovered, providing a novel way to target the dysregulated Hippo-YAP pathway in mesothelioma and other YAP-driven cancers and diseases.

MOLECULAR CANCER THERAPEUTICS (2021)

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Review Biotechnology & Applied Microbiology

Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine

Anwesha Dey et al.

NATURE REVIEWS DRUG DISCOVERY (2020)

Article Biochemistry & Molecular Biology

YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role

Matthias Van Haele et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

Review Gastroenterology & Hepatology

Liver Cancer Gene Discovery Using Gene Targeting, Sleeping Beauty, and CRISPR/Cas9

Julia E. Kieckhaefer et al.

SEMINARS IN LIVER DISEASE (2019)

Review Medicine, General & Internal

Hepatocellular Carcinoma

Augusto Villanueva

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Article Biochemistry & Molecular Biology

p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression

Sung-Hwan Moon et al.

Review Cell Biology

Role of the transcriptional coactivators YAP/TAZ in liver cancer

Shihao Zhang et al.

CURRENT OPINION IN CELL BIOLOGY (2019)

Review Cell Biology

Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine

Ivan M. Moya et al.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)

Review Oncology

YAP/TAZ Signaling and Resistance to Cancer Therapy

Chan D. K. Nguyen et al.

TRENDS IN CANCER (2019)

Article Oncology

The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1

Helena J. Janse van Rensburg et al.

CANCER RESEARCH (2018)

Article Gastroenterology & Hepatology

Combinatorial genetics in liver repopulation and carcinogenesis with a in vivo CRISPR activation platform

Kirk J. Wangensteen et al.

HEPATOLOGY (2018)

Review Cell Biology

YAP/TAZ upstream signals and downstream responses

Antonio Totaro et al.

NATURE CELL BIOLOGY (2018)

Article Medicine, General & Internal

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

D. Adams et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

News Item Multidisciplinary Sciences

Gene-silencing drug approved

Heidi Ledford

NATURE (2018)

Article Oncology

Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival

Ahmedin Jemal et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)

Article Oncology

Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival

Ahmedin Jemal et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)

Article Multidisciplinary Sciences

Crystal structure of TAZ-TEAD complex reveals a distinct interaction mode from that of YAP-TEAD complex

Hung Yi Kristal Kaan et al.

SCIENTIFIC REPORTS (2017)

Review Biochemistry & Molecular Biology

Implementing Genome-Driven Oncology

David M. Hyman et al.

Editorial Material Biochemistry & Molecular Biology

Srebp2: A master regulator of sterol and fatty acid synthesis

Blair B. Madison

JOURNAL OF LIPID RESEARCH (2016)

Article Biochemistry & Molecular Biology

Functional and Clinical Evidence That TAZ is a Candidate Oncogene in Hepatocellular Carcinoma

Yan Guo et al.

JOURNAL OF CELLULAR BIOCHEMISTRY (2015)

Article Oncology

The emerging roles of YAP and TAZ in cancer

Toshiro Moroishi et al.

NATURE REVIEWS CANCER (2015)

Article Cell Biology

Metabolic control of YAP and TAZ by the mevalonate pathway

Giovanni Sorrentino et al.

NATURE CELL BIOLOGY (2014)

Review Physiology

THE BIOLOGY OF YAP/TAZ: HIPPO SIGNALING AND BEYOND

Stefano Piccolo et al.

PHYSIOLOGICAL REVIEWS (2014)

Review Gastroenterology & Hepatology

Statins Are Associated With a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-analysis

Siddharth Singh et al.

GASTROENTEROLOGY (2013)

Article Biochemical Research Methods

CRISPR interference (CRISPRi) for sequence-specific control of gene expression

Matthew H. Larson et al.

NATURE PROTOCOLS (2013)

Article Biochemistry & Molecular Biology

Nuclear CDKs Drive Smad Transcriptional Activation and Turnover in BMP and TGF-β Pathways

Claudio Alarcon et al.

Article Biochemistry & Molecular Biology

TEAD Transcription Factors Mediate the Function of TAZ in Cell Growth and Epithelial-Mesenchymal Transition

Heng Zhang et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2009)

Article Gastroenterology & Hepatology

A facile method for somatic, lifelong manipulation of multiple genes in the mouse liver

Kirk J. Wangensteen et al.

HEPATOLOGY (2008)

Article Medicine, General & Internal

Sorafenib in advanced hepatocellular carcinoma

Josep M. Llovet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Article Multidisciplinary Sciences

A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome

M Murakami et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)